Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2016

Open Access 01-12-2016 | Erratum

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Authors: Denise A. Yardley, Adam Brufsky, Robert E. Coleman, Pierfranco F. Conte, Javier Cortes, Stefan Glück, Jean-Mark A. Nabholtz, Joyce O’Shaughnessy, Robert M. Beck, Amy Ko, Markus F. Renschler, Debora Barton, Nadia Harbeck

Published in: Trials | Issue 1/2016

Login to get access

Excerpt

Unfortunately, the original version of this article [1] contained a few formatting errors which have been corrected via an update. In the eighth paragraph of the background there was an error. The original read as, “A phase II study evaluating the combination of nab-paclitaxel plus carboplatin as 199 first-line treatment for mTNBC is currently under way [31].” But should have read as “A phase II study evaluated the combination of nab-paclitaxel plus carboplatin a first-line treatment for mTNBC [31].” …
Literature
1.
Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015;16:575.PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
Authors
Denise A. Yardley
Adam Brufsky
Robert E. Coleman
Pierfranco F. Conte
Javier Cortes
Stefan Glück
Jean-Mark A. Nabholtz
Joyce O’Shaughnessy
Robert M. Beck
Amy Ko
Markus F. Renschler
Debora Barton
Nadia Harbeck
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Trials / Issue 1/2016
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-016-1195-6

Other articles of this Issue 1/2016

Trials 1/2016 Go to the issue

Erratum

Erratum to: CASPER plus (CollAborative care in screen-positive EldeRs with major depressive disorder): study protocol for a randomised controlled trial

Study protocol

Effects of the pattern of glucocorticoid replacement on neural processing, emotional reactivity and well-being in healthy male individuals: study protocol for a randomised controlled trial

Study protocol

Attention training for infants at familial risk of ADHD (INTERSTAARS): study protocol for a randomised controlled trial

Study protocol

Cognitive remediation versus active computer control in bipolar disorder with psychosis: study protocol for a randomized controlled trial

Study protocol

A trial to determine whether septic shock-reversal is quicker in pediatric patients randomized to an early goal-directed fluid-sparing strategy versus usual care (SQUEEZE): study protocol for a pilot randomized controlled trial

Study protocol

Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial